How KIMCo Is Orchestrating Korean Pharma Collaborations
Korean Firms "Should Collaborate, Not Compete"
Executive Summary
KIMCo CEO Kevin Kyunghwa Huh talks about the consortium's efforts to become a platform of collaboration for Korean pharmas, including plans for the latest joint investment project as well as how the domestic industry is evolving in terms of globalization and open innovation.
You may also be interested in...
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
AVEO Acquisition Brings LG Chem Marketed Oncology Drug, US Commercial Footprint
The acquisition of the US oncology-focused firm will immediately build the commercial presence of the affiliate of the major South Korean conglomerate in oncology through Fotivda, while bringing LG Chem a step closer to its ambitions of becoming a major global pharma operation.
Celltrion Eyes M&A, Global Expansion And Novel Drugs As Founder Returns
Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.